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John F. DiPersio,1 Anthony D. Ho,2 Jessie Hanrahan,3 Frank J. Hsu,3 Stefan Fruehauf4Autologous transplantation of peripheral blood (PB) hematopoietic stem cells (HSCs) is a widely used strat-
egy for reconstitution of blood cells following high-dose chemotherapy for hematologic malignancies such as
multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and acute myeloid leukemia (AML), among others.
Stem cells for transplantation are usually obtained from PB after treatment with chemotherapy with or with-
out cytokine, usually granulocyte-colony stimulating factor (G-CSF), or after treatment with cytokine alone.
The use of autologous peripheral blood stem cells (PBSCs) for transplantation is associated with the risk of
contamination of the graft with tumor cells; whether this impacts response rates, progression-free survival
(PFS), and overall survival (OS) is still debatable. This review summarizes the controversy surrounding tumor
cell mobilization (TCM), the complexity of detection of minimal residual diseases, the available diagnostic
tools, differences in TCM with available mobilization regimens, and the potential effect of TCM on clinical
outcome. Collectively, these data suggest that new treatment paradigms to manage hematologic malignan-
cies, such as MM, NHL, and AML, are needed and should focus on increasing the chemosensitivity of the
tumor and eliminating residual disease.
Biol BloodMarrow Transplant 17: 943-955 (2011) 2011 Published by Elsevier Inc. on behalf of American Society for Blood
and Marrow TransplantationKEY WORDS: Plerixafor, Tumor cell mobilization, Hematopoietic stem cell transplantation, Hematologic
malignancy, Non-Hodgkin’s lymphoma, Multiple myeloma, Acute myeloid leukemiaINTRODUCTION
Tumor cells can be detected in the peripheral
blood (PB) of patients with various cancer types and
can contaminate autologous stem cell products derived
from the bone marrow (BM) or from apheresis [1-3].
Standard cancer treatment such as chemotherapy or
radiation might by itself induce significant mobilization
of tumor cells into the PB, and has been reported to
be associated with metastases [4]. Similarly, common
methods employed to mobilize peripheral blood
stem cells (PBSCs) such as chemotherapy and the use
of agents such as cytokines might also mobilize tumorshington University, St. Louis, Missouri; 2Department of
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6/j.bbmt.2010.10.018cells and lead to significant contamination of the
apheresis products [4-6].
Given the low number of tumor cells compared
with normal cells and the heterogeneity of tumor cells,
their detection presents a major challenge. Tumor cell
detection is further complicated by the fact that very
few tumor-specific cellular markers exist, and many of
the available assays are exploratory in nature. Addition-
ally, the sensitivity and specificity of the detection
methods vary enormously and are highly dependent
upon the methods employed and the source of the cells
analyzed (eg,BMsample, apheresis sample,PB sample).
It is possible that tumor cells in the reinfused
apheresis product could lead to relapse. In patients
with acute myeloid leukemia (AML) or neuroblastoma
who relapsed after receiving genetically marked auto-
logous BM cells for autologous stem cell transplanta-
tion, the genetic marker (neomycin-resistant gene)
could be detected by polymerase chain reaction
(PCR) in the relapsed malignant cells, suggesting
that contaminating malignant cells in the autologous
stem cell product contributed, at least in part, to re-
lapse after transplant [7]. A genetic marking study
showed that Ph1 cells present in autologous trans-
plants of patients with chronic myelogenous leukemia
can contribute to relapse after transplantation [8].
Nevertheless, these studies do not rule out the likely943
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detected at the time of relapse after autologous stem
cell transplantation are because of the regrowth of re-
sidual disease following incomplete eradication of tu-
mor cells by high-dose chemotherapy and radiation
therapy [9,10]. This review, with a focus on
hematologic malignancies such as multiple myeloma
(MM), non-Hodgkin lymphoma (NHL), and AML,
provides an overview of themethods used for detection
of malignant cells in these entities, and of the levels of
tumor cell contamination found following the more
common methods of mobilization, including chemo-
therapy, cytokines, and the newly approved mobilizing
agent, plerixafor.METHODS OF TUMOR CELL DETECTION
Multiple methods have been developed for the
detection of tumor cell mobilization, including immu-
nocytochemistry [11-13], cell culture [14], flow cyto-
metry, and PCR (both allele-specific oligonucleotide
[ASO] and quantitative real-time assay for tumor-
associated markers). The sensitivity of the tumor cell
mobilization (TCM) assays can be increased by analyz-
ing multiple samples, increasing the number of cells
tested in the sample, and employing sensitive reverse-
transcriptase PCR methods (RT-PCR). Flow cytome-
try is considered a low-sensitivity method capable of
detecting 1 tumor cell per 1000 PBMCs [15]. Compar-
atively, quantitative PCRmethods are highly sensitive,
detecting as few as 1 tumor cell per million PBMCs.
Ultimately, the applicability of eachmethodwill be de-
termined by the level of tumor contamination consid-
ered to be clinically relevant and the detection limits of
each assay.
Flow Cytometry
Malignancies such asMM arise from amonoclonal
population of B cells, and therefore each tumor cell ex-
presses a unique immunoglobulin (Ig) molecule. In ad-
dition, plasma cells from patients with MM generally
have an abnormal DNA content (aneuploidy) and an
increased RNA content [16-18].
In this detection method, cells are labeled with
anti-Ig light chain and/or anti-Ig heavy chain anti-
bodies conjugated to fluorochromes, and the DNA is
stained. The cells are then analyzed by flow cytometry,
which allows for automated cellular analysis [19]. The
results of this method can be easily analyzed, profiling
normal cells versus tumor cells. The data from this
method are presented as the percentage of Ig light
chain cells (kappa and lambda), as a DNA index (ratio
of G1/0 DNA peaks of tumor and control cells) [20],
and/or as an RNA index (ratio of mean RNA content
of tumor G1/0 cells to control lymphocytes) [18]. De-
tection of Ig light chain restriction and a DNA index
of anything other than 1 is indicative of tumor cells.Other markers such as CD38, in combination with
DNA content, can also be used in a similar manner
to increase the specificity of the assay [21,22].
Additionally, as mentioned above, MM cells may
have increased cytoplasmic immunoglobulin (CIg),
which can be detected by flow cytometry [20]. These
data are represented as a CIg index (ratio of median
CIg fluorescence intensities of aneuploid and diploid
G1 cells from the same patient sample).
Recently, a monoclonal antibody that recognizes
a 19-amino acid polypeptide containing a unique C-
terminus of the nucleophosmin 1 (NPM1) mutated
protein has been generated, which can be used to
detect AMLwith this NPM1mutation using immuno-
histochemistry [23].
Flow cytometry is highly reproducible, relatively
inexpensive, and a quick throughput method [24].
However, flow cytometry may require large sample
volumes [24], and the sensitivity of this assay is limited
to approximately 1 tumor cell per 1000 PBMCs [25].
Because the technique of flow cytometry is to count
cells labeled with a fluorochrome, for a low-frequency
event such as tumor cell contamination, a large number
of PBMCs must be counted in order to accurately de-
tect low quantities of tumor cells. Even with modern
high-speed machines, there are practical limits to the
number of cells that can be analyzed by this method,
because of the time required to perform these tests
and the quantity of cells available. In addition, the spec-
ificity of the assaymay be impacted by the reagents used
and by their ability to accurately distinguish tumor cells
from normal cells [24,26]. Immunophenotyping using
multiple antibodies can increase the sensitivity of flow
cytometry to 1:105 [15], allowing for the detection of
rare, contaminating aberrant plasma cells [15,27].
However, this can be technically challenging, as
a large quantity of cells to be analyzed is required to
achieve accurate results.PCR Analysis
PCR can be used to detect the presence (or ab-
sence) of tumor cells. Tumor cells from a specific can-
cer type generally have unique DNA sequences, often
resulting from gene rearrangements, which are absent
in normal cells. The unique DNA sequence can be de-
tected by designing specific PCR primers capable of
amplifying the tumor-specific sequences of DNA.
PCR has important advantages in that the method re-
quires very little sample and is relatively simple to per-
form. Disadvantages of the PCR method include its
high rate of false positives and the fact that very few
gene sequences have been identified that may be
broadly applied to a cancer indication (eg, BCL-2 for
certain lymphomas, Bcr-Abl for chronic myelogenous
leukemia). In many instances, gene rearrangements
and mutations are specific to an individual patient’s
Biol Blood Marrow Transplant 17:943-955, 2011 945Relevance of Tumor Cell Mobilization in Autologous Transplanttumor and are not applicable to other patients with the
same type of cancer. In these cases, a patient-specific
detection test must be developed for each individual.
The detection sensitivity of PCR is 1 tumor cell per
105 to 107 PBMCs [24].
Patient-specific PCR to detect TCM in multiple
myeloma and NHL
InMM and B cell NHL, malignant cells arise from
a single B cell clone. During B cell ontogeny, a func-
tional immunoglobulin (Ig) heavy chain gene complex
is formed. The formation of the Ig heavy chain results
in a unique gene sequence specific to the B cell clone
from which it arose [28,29]. Mutational events occur
at the junctional splice sites and often within the
complementarity determining regions (CDRs). The
CDRs represent primary contact points for antigen
interaction; these ‘‘binding sites’’ are often subject to
significant mutational events following antigen
exposure. The CDR3 region of the Ig heavy chain
variable gene spans 3 different Ig gene segments:
VH-D-JH. Because of the enormous genetic diversity
of this region, as well as of the other CDRs, these Ig
heavy chain variable gene segments represent true
tumor-specificmarkers. All tumor cells in an individual
patient share an identical rearranged Ig gene sequence,
resulting from rearrangements of the VH, D, and JH
gene segments [28,29]. B cell–specific primers, which
are patient specific, can be designed to these gene seg-
ments and used to detect tumor cells by sensitive PCR
techniques.
Quantitative PCR can be performed to amplify the
CDR3 region of the clonally rearranged VDJ segments
of the Ig heavy chain gene [30,31] using allele-specific,
and therefore patient-specific, oligonucleotides
(ASO-PCR) [2,32,33]. ASO-PCR can be used to spe-
cifically detect these uniqueDNA sequences and assess
the mobilization of MM tumor cells [34]. The quanti-
tative ASO-PCR method determines the frequency of
tumor genes with respect to the total DNA content.
This result is then used to calculate the tumor cell fre-
quency compared with total PBMCs. Using the total
PBMC concentration, the total tumor cell concentra-
tion can be calculated. The detection sensitivity of
this method is 1:104 cells [24] to 1:106 cells [24,34,35].
To perform this assay, a sample of tumor must be
obtained, the Ig VH gene segment must be sequenced,
and tumor-specific primers must be designed and
tested beforehand. Once the PCR detection assay is es-
tablished, total genomic DNA is isolated from PB,
apheresis product, or other sample. The isolated
DNA and the gene-specific primers are then used in
a PCR reaction. Quantitative PCR methods can be
used to determine the level of contamination within
a sample, or in the case of no DNA amplification, to
indicate the absence of tumor cells at the level of the
sensitivity of the assay. This method is extremelylaborious (requiring original patient tumor samples
and primers designed for each patient), technically
challenging, and expensive. ASO-PCR, however, is
highly sensitive, tumor-specific, and requires a small
sample.
PCR for chromosomal translocations to detect
TCM in NHL
Approximately 80% of patients with NHL with
follicular histology have a translocation t(14;18) of
the BCL-2 gene [36]. The presence of this transloca-
tion can be exploited through the use of PCR in
diagnostic settings [37-39].
Approximately 60% to 70% of breakpoints fall
within a well-defined area, known as the major break-
point region (MBR) of the 30-untranslated part of the
BCL-2 gene. Using primers that flank the most com-
mon consensus regions of the MBR and modified to
fluoresce when hybridized with complementary
DNA, PCR can be used to detect BCL-2 gene rear-
rangements [26]. Methods such as quantitative real-
time PCR can be used to detect translocations down
to 0.002%, or 1/50,000 cells.
For this assay, total genomic DNA is isolated from
PB, apheresis product, or other sample. The isolated
DNA and the gene-specific primers are then used in
a quantitative PCR reaction; the amplification of the
b-actin gene is used as a control. Standard curves are
calculated for the BCL-2 rearrangement and b-actin
and are used to quantify DNA within each sample.
These curves control for PCR efficiency and detection
limits. A typical lower limit of detection for this assay is
0.01 ng of tumor DNA in a 1-mg DNA sample per
PCR, which correlates to approximately 2 tumor cells
per PCR. If no BCL-2 amplification is detected in the
PCR product, this indicates the absence of the t(14;18)
translocation in the MBR of the BCL-2 gene or that
levels are below the limit of detection.
This method is highly sensitive, and commercial
primers are available that can be used for all patients.
However, rearrangements involving other regions,
including the minor breakpoint cluster, are not detect-
able with this assay. Additionally, given that the trans-
location is not found in all patients with NHL, this
method is not applicable to all patients and could
lead to false negatives. Another disadvantage of this
method is that the t(14;18) translocation is observed
with increasing frequency in normal lymphocytes as
a function of age [40].PCR to Detect TCM in AML
Aberrations in the NPM1 gene, especially NPM1-
mutA, represent the most common gene alteration in
AML [41,42]. NPM1 mutations display stability and
high prevalence over the course of the disease.
Investigators have shown that an ASO-RT-PCR assay
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that included 52 patients with AML, ASO-RT-PCR
detected NPM1-mutA in 21 patients, with a sensitivity
of 1:100 and, using a seminested method that incor-
porated a forward primer to enhance sensitivity,
1:100,000 [42]. It should be pointed out, however,
that this assay has not been properly validated to detect
NPM; consequently, other mutations, even in mutA,
may render the assay nonfunctional. The translocation
t(8;16)(p11;p13), which is associated with myelomono-
cytic differentiation, represents another common ge-
netic abnormality in AML cells that may be detected
with RT-PCR [43]. Fms-like tyrosine kinase-internal
tandem duplication (Flt3-ITD)-positive AML cells
can also be detected by PCR, but no clinical correlation
has been made associating the presence of contaminat-
ing flt3-ITD–positive AML cells with the outcome of
autologous stem cell transplantation. This is in con-
trast to contamination of autologous stem cell prod-
ucts with acute promyelocytic leukemia (APL) cells
harboring the PML-RAR-a fusion gene, which can be
detected by RT-PCR. The presence of contaminating
PML-RAR-a–positive APL in autologous mobilized
PBMC has been associated with decreased leukemia-
free survival after autologous stem cell transplantation
[44]. No studies have demonstrated that either granu-
locyte colony-stimulating factor (G-CSF) or chemo-
therapy plus G-CSF has a differential effect of
mobilizing AML cells carrying NPM1, flt3-ITD
mutations, or PML-RAR-a fusion genes.
PCR to Detect TCM in Neuroblastoma
In a study of 11 patients with neuroblastoma or
Ewing’s sarcomas, RT-PCR was used to detect
neuroblastoma-specific antigens (MoAb14-2Ga, UJ
127.11, 5.1.H11, and Anti-Thy-1) in PBSC and BM
harvests [45]. Immediately before harvest, clinical his-
tology revealed no tumor cells in BM. Yet tumor cells
were detected by RT-PCR and immunochemistry as-
says in 9 of 11 (82%) of PBSC harvests and in 8 of 9
(89%) of the BM harvests. Moreover, PBSC mobiliza-
tion with cyclophosphamide and G-CSF did not affect
the incidence or level of contamination in PBSCs.
Other investigators have used RT-PCR to examine
the expression of additional markers that are highly
expressed in neuroblastoma—tyrosine hydroxylase
(TH), neuroendocrine protein gene product 9.5,
ElAVL-4, and GD2 synthetase [46]. In this analysis,
TH was shown to be the most specific marker for the
detection of neuroblastoma.
Tumor Cell Contamination of PB Prior to
Mobilization
Tumor cells can be found circulating in the PB of
patients with both hematologic malignancies and solid
cancers, especially when the cancer is measurable andnot in a minimal disease state. One study showed
a wide variation prior to treatment (ie, any chemother-
apy) in the frequency/number of circulating tumor
cells in PB of patients with MM. Among 14 patients
with MM, 13 tested positive for the presence of tumor
cells by ASO-PCR, with tumor cell frequency varying
for 12 patients from 0.001% to 1.0% and 32% for 1 pa-
tient [2,3]. In another study of 23 patients withMM, all
patients had detectable circulating plasma cells with
a range of 0.1% to 1.8% of mononuclear cells
(MNC) fraction [47]. Some studies have reported
a correlation of tumor burden and stage of disease
with the incidence of circulating tumor cells [48-52];
others, however, have reported that the incidence of
tumor cells in PB in certain cancers such as MM
appeared to be independent of BM tumor burden
and stage of disease [3,53].Tumor Contamination of Stem Cell Products
After Mobilization
Tumor cell contamination of PBSC products rou-
tinely occurs and has been reported following the use
of all common mobilization methods [54]. A wide var-
iation in the frequency of tumor cell levels, ranging
from 0.01% to .10%, has been reported in virtually
all mobilized PBSC harvests [55]. The kinetics of tu-
mor cell mobilization, the underlying residual tumor
burden in the patient, and the mobilization method
used are important factors that impact the contamina-
tion of the apheresis product. Several groups have re-
ported that higher proportions of hematopoietic
progenitor cells are observed early during apheresis
(ie, the first 2 days), whereas peak levels of myeloma
cells occur in the later stage of apheresis [1,56].
However, other studies have found no variation in
the kinetics of tumor cell and CD341 stem cell
mobilization [27,37,57,58].
In addition to G-CSF, several agents have been
shown to mobilize PBSC, including pegylated G-CSF
(pegfilgrastim), natalizumab, thrombopoietin, and
chemokines such as stem cell factor, macrophage in-
flammatory protein-1a, interleukin-8, and stromal cell-
derived factor-1 (SDF-1) analog, among others [59,60].
However, the only Federal Drug Administration–
approved agents are G-CSF, granulocyte-macrophage
colony stimulating factor (GM-CSF), and the chemo-
kine receptor 4 (CXCR4) antagonist plerixafor.
Chemomobilization
Prior to the development of cytokines for stem cell
mobilization, it was noted that there were transient in-
creases in hematopoietic stem cells in PB following the
administration of myelosuppressive chemotherapy
[61,62]. The earliest protocols for the mobilization
of stem cells used chemotherapy alone [63,64], and
later protocols used chemotherapy followed by daily
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[65-67]. In general, chemotherapeutic agents induce
stem cell mobilization by reducing BM hemato-
poietic cell reserves and forcing stem cell expansion
and hematopoiesis [68].
Studies have shown that patients with MM have
between 0.1% and 1% clonal B cells in hematopoietic
stem cell collections following chemomobilization, re-
sulting in the infusion of 0.5 to 5  108 myeloma cells
with each transplant [47,55,69,70]. A recent study by
Kopp et al. [6] examined the amount of tumor cell
contamination in the stem cell product and the result-
ing outcome following transplantation. The study
reported that 27% of stem cell products from 60
patients withMMwere contaminated with large quan-
tities of tumor cells (.4.5  105 cells/kg) following
mobilization with chemotherapy or chemotherapy
plus G-CSF, and 73% of stem cell products were con-
taminated with low levels of tumor cells (#4.5  105
cells/kg). A study by Ho et al. [71] on the presence of
contaminating tumor cells in PBSC and its influence
on outcomes showed tumor contamination of the
PBSC graft in 36% (32/89) of patients with NHL
and in 25% (17/69) of patients with MM following
chemomobilization using varying regimens (Table 1).
Mobilization with cytokines
The use of cytokines (most commonly, G-CSF and
GM-CSF) began in the late 1980s to early 1990s
following the report of the mobilizing effects of these
agents [66,67]. A later report described long-term
hematopoietic reconstitution in patients transplanted
with only cytokine-mobilized PBSCs [76]. The most
commonly used cytokine, G-CSF, works by granulo-
cyte expansion/activation, protease release, and cleav-
age of adhesion molecules [68,77].
Tumor contamination of the PB apheresis product
has also been noted in patients receiving only cytokines
for mobilization. In a retrospective study of 61 patients
with NHL, PBSC samples were examined from 26
patients who did not receive a mobilizing regimen
and 35 patients who had mobilization of stem cells
with cytokines (22 with G-CSF and 12 with GM-
CSF) [72]. Among patients in the cytokine-mobilized
group, 37% had tumor contamination in the apheresis
product, compared with 19% of the nonmobilized
group, although this difference was not statistically
significant.
Studies comparing mobilization methods
An early study in 8 patients with MM compared
the tumor load of the apheresis product following mo-
bilization with G-CSF and following mobilization
with G-CSF plus cyclophosphamide [34]. This study
concluded that mobilization by cyclophosphamide
plus G-CSF led to a lower number of malignant cells
per CD341 cells in the apheresis product comparedwith G-CSF alone. A later study that examined re-
sponse and survival rates with various treatment
regimens in 135 patients with MM reported graft con-
tamination with monoclonal plasma cells following
mobilization of stem cells. Of the 102 patients receiv-
ing G-CSF alone, 25% had tumor contamination, and
of the 33 patients receiving chemomobilization, tumor
contamination was noted in 51% [5]. In a randomized
study of 47 patients with lymphoma, PCR tumor cell
data were available for 22 patients with NHL; 11
patients received mobilization with G-CSF alone,
and 10 patients received chemotherapy and G-CSF
[73]. In both groups, a high percentage of tumor
contamination of the harvested PBSC product was
seen (in 92% and 90%, respectively) (Table 1).Plerixafor plus G-CSF
Recently approved for marketing in the United
Sates for use with G-CSF for stem cell mobilization,
plerixafor is a selective and reversible antagonist of
CXCR4, disrupting its interaction with SDF-1 and
thereby releasing hematopoietic stem cells into the
circulation.
Plerixafor is not approved for stem cell mobiliza-
tion in patients with leukemia, owing to a potential
for mobilizing leukemic cells. This very property is be-
ing explored in investigational trials to determine
whether plerixafor can sensitize leukemic cells to
chemotherapy and is an area of development [78-82].
The effect of plerixafor plus G-CSF on tumor cell
contamination has been investigated in patients with
NHL [76,83,84] and those with MM [74,84].
Samples were collected for the evaluation of tumor
cell contamination from 11 patients with NHL [75]
and from 10 patients [84] and 7 patients [74] with
MM who were in plerixafor clinical trials. In the sam-
ples of 11 patients with NHL, 5 received G-CSF alone
and 6 received plerixafor plus G-CSF. Samples were
analyzed by quantitative PCR for BCL-2 translocation
[75]. Of these NHL patients, 10 had undetectable
levels of translocated BCL-2 in the apheresis product,
and 1 patient who received G-CSF alone had detect-
able levels (Table 1).
Tricot et al. [84] analyzed PB samples by flow cy-
tometry in 10 patients with MM. A total of 9 paired
samples were available for analysis before and after
the first and second dose of plerixafor. None of the
PB samples showed .1% light chain–restricted cells,
except for the first apheresis product of 1 patient,
who had 2% kappa cells with a DNA index of 1 and
1% lambda cells with a DNA index of 1. Plasma cells
with aneuploid DNA content were not observed in
any of the samples.
In the 7 patients with MM, samples for PBMC
were obtained at baseline prior to any therapy, follow-
ing G-CSF and before plerixafor administration, and
Table 1. Mobilization Methods and Tumor Cell Contamination of Apheresis Products
First Author
(Reference) Mobilization Method
Number of Patients/
Disease Type
Method for Detection
of Tumor Cells
Percentage of Patients with
Tumor Cells Detected Level of Contamination
Gazitt [55] Chemotherapy 10/MM PCR 100% (10 patients) <0.4-8400  104
Ho [71] Chemotherapy 89/NHL
69/MM
PCR 36% of collections contaminated with NHL
tumor cells
25% of collections contaminated with MM
tumor cells
Reported as detectable or not detectable
according to the method (method sensitive to
detect 1:100,000 cells)
Kopp [6] Chemotherapy and G-CSF 60/MM Flow cytometry 27% of collections contaminated with high levels
73% of collections contaminated with low levels
#4.5  105 tumor cells/kg
>4.5  105 tumor cells/kg
Lemoli [47] Chemotherapy and G-CSF 23/MM Flow cytometry 100% (23 patients) Mean 5 0.7% circulating myeloma cells (range:
0.2%-2.7%)
Schiller [69] Chemotherapy and G-CSF 37 (14 had tumor
contamination
measured)/MM
PCR 57% (8/14) 0.23%-0.0015%
Demirkazik [72] Cytokines 26/NHL (not mobilized)
35/NHL (mobilized)
PCR 37% of collections contained tumor
contamination in the mobilized group
compared with 19% in the nonmobilized
group
G-CSF mobilized group: median GM-CFC 104
kg/liter blood 5 0.21 (0.017-5.8)
Nonmobilized group: median GM-CFC  104
kg/L blood 5 0.0054 (0.0001300.072)
Anagnostopoulos [5] G-CSF or chemotherapy 33/MM (G-CSF alone)
102/MM (chemotherapy)
Flow cytometry 25% of collections contaminated with tumor
cells (G-CSF alone)
51% of collections contaminated with tumor
cells (chemotherapy)
All patients: B-2 microglobulin median 5 3.2
(range: 0.2-34.1)
Narayanasami [73] G-CSF or chemotherapy
and G-CSF
47/lymphoma (TCM data
reported on 22
patients with NHL)
PCR 11/12 patients (92%) in G-CSF-alone arm
9/10 patients (90%) in chemotherapy + G-CSF
arm
Not reported
Cremer [34] G-CSF or chemotherapy
plus and G-CSF
8/MM PCR All 8 patients had detectable malignant cells in
the apheresis product
0.0006%- 0.256%
Fruehauf [74] Plerixafor plus G-CSF 7/MM PCR 3/7 had detectable tumor cells;
4/7 had no detectable tumor cells
Observed fold change from pre-plerixafor to
pre-apheresis: 0.11- to 1.08-fold
DiPersio [75] Plerixafor plus G-CSF 11/NHL (5 G-CSF only;
6 plerixafor plus G-CSF)
PCR 1/5 G-CSF had detectable levels of
tumor cells;
6/6 had no detectable levels of tumor cells
Not reported
G-CSF indicates granulocyte-colony stimulating factor; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PCR, polymerase chain reaction; TCM, tumor cell mobilization.
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These samples were examined for TCM using a highly
sensitive and tumor-specific CDR3 PCR test [74].
Consistent with other studies, G-CSF treatment alone
resulted in an increase of mobilization of tumor cells
over baseline. In contrast, after receiving plerixafor, 3
of 7 patients had slightly increased tumor cells in the
PB compared to G-CSF alone, whereas 4 of 7 had
decreased tumor cells. For all patients, the change in
tumor cell level ranged from 0.11 to 1.08 times the
pre-plerixafor level; therefore, there did not appear
to be specific mobilization of tumor cells.
In summary, although the total number of patients
examined overall was limited, there did not appear to
be an increase of tumor cells in the blood or apheresis
product following administration of plerixafor greater
than that observed or expected with G-CSF. Thus,
contamination of an apheresis product following
mobilization with plerixafor and G-CSF would be
expected to be similar to that occurring with standard
G-CSF mobilization in patients with NHL or MM.Effect of Tumor Cell Contamination on Clinical
Outcomes
Early reports examining the presence of tumor
contamination in PBSC products and clinical outcome
(response and survival) of patients who undergo
transplantation with these products have reached dif-
ferent conclusions regarding the clinical implications
of this finding [69,85]. A recent study by Ho et al.
examined NHL (n 5 89) and MM (n 5 69) patients
undergoing autologous stem cell transplants (Table 2)
[71]. The study compared the outcome of patients who
underwent transplantation with hematopoietic stem
cells (HSCs) free of tumor cells with that of patients
who underwent transplantation with contaminated
HSCs. The results of this study demonstrated that
the contamination ofHSCs with tumor cells had no in-
fluence on progression-free survival (PFS) or overall
survival (OS), even when aggressive or indolent histol-
ogies are considered separately. Similarly, another
study found that the tumor cell content of PB progen-
itor cell grafts was not predictive of clinical outcome in
patients with diffuse B cell lymphoma and follicular
lymphoma [86]. Finally, another study in 61 NHL pa-
tients found that lymphoma contamination of trans-
planted apheresis products had no apparent impact
on event-free (EFS) and OS [72].
In contrast, other studies have reported poorer
clinical outcomes in patients who underwent trans-
plantation with HSCs contaminated with tumor cells
[30,88,91,92,94]. The study by Kopp et al. [6] de-
scribed a correlation between tumor contamination
and outcome in patients with MM receiving chemo-
mobilized stem cell products. The results of this study
suggest that the level of tumor cell contaminationcorrelated with a poorer OS. However, the level of tu-
mor cell contamination was high (.4.5  105 cell/kg).
(If one assumes a patient weight of 85 kg and an apher-
esis cell concentration of approximately 100  106 PB
mononuclear cells [PBMC] per mL, this correlates to
roughly 4 tumor cells per 1000 PBMC.) In this study,
lower quantities of tumor had no significant impact on
PFS orOS. These findings indicate that the level of tu-
mor cell contamination of the apheresis product needs
to be very high in order to affect clinical outcome and
that minimal or moderate amounts of contamination
may not be clinically significant. Of note, the use of
chemotherapy for mobilization did not reduce the
subsequent collection of tumor cells or the purported
impact on outcome.
In patients with AML, early (after first remission)
and late autologous PB transplantations were shown
to result in worse outcomes compared with BM trans-
plantation in terms of survival without evidence of re-
lapse or disease progression [95,96]. This difference
was attributed to the possible recruitment of tumor
cells after growth factor–driven mobilization, and in
turn, to higher tumor cell contamination of the PB au-
tographs [95]. There has been a trend away from the
use of autologous transplantation for the treatment
of AML [97]; thus, the impact of tumor cell contami-
nation of the apheresis product is of diminishing
relevance in current clinical practice.
In patients with NHL, such as refractory follicular
lymphoma and mantle cell lymphoma, in vivo purging
and stem cell mobilization with rituximab and high-
dose cytarabine in conjunction with G-CSF have
been shown to yield lymphoma-free PB progenitor
cells (product of leukapheresis negative for Bcl-2
or Bcl-1) suitable for autologous transplantation
[98-100]. Patients who underwent this process,
which was preceded by debulking chemotherapy,
experienced positive outcomes, with all patients still
in complete clinical and molecular remission after
a median follow-up of 8.5 months [98]. Rituximab
has been incorporated into autologous PB transplanta-
tion protocols to minimize disease activity and provide
effective in vivo purging [101].
Tumor cell contamination has driven the develop-
ment of methods to reduce, or purge, the quantity of
tumor cells within the stem cell product. These ‘‘purg-
ing’’ methods have included the direct removal of
tumor cells by antibodies plus complement, by mag-
netic bead separation, exposure of the stem cell prod-
uct to chemotherapy in vitro, or the selection and use
of purified stem cells. Because malignant cells from
patients with MM and NHL generally do not express
CD34, positive selection of CD341 cells has been
used to separate stem cells from tumor cells. Studies
have demonstrated that this method markedly reduces
tumor contamination by several logs (median 2 to 3
logs) [69,102-106]. However, despite large reductions
Table 2. Effect of Tumor Cell Contamination of Apheresis Products on Clinical Outcomes
First Author (Reference) Mobilization Method
Number of
Patients/Disease Type Conclusions
Blystad [86] Chemotherapy plus G-CSF 43/NHL The level of contamination of the PBPC/CD34+ cells ranged from 0% to 8.3%. No relationship could be shown between the total
number of tumor cells infused and relapse. Patients receiving PCR-positive or PCR-negative PBPC grafts had similar
progression-free survival (P 5 .49).
Bourhis [87] Chemotherapy and G-CSF 111/MM Despite significant tumor cell reduction, CD34+ selection does not reduce RR and increases the risk of severe posttransplant
infections. There was also no difference in RR between patients in either arm who received grafts with detectable tumor cells
and those receiving grafts with no detectable tumor cells. This suggests that reinfused tumor cells may not be the main cause of
relapse after autologous transplant in myeloma.
Brown [88] Chemotherapy or
chemotherapy and G-CSF
103/NHL The only predictors of decreased progression-free survival proved to be histologic BM involvement at time of harvest (HR, 2.27,
95% CI, 1.3-3.9, P < .004) and PCR detectable disease in the BM product after purging (HR, 4.18, 95% CI, 1.99-8.8, P5 .0002).
No significant predictors of overall survival were identified.
Ho [71] Chemotherapy 89/NHL
69/MM
Patients with MM or NHL with contaminating tumor cells in autologous PBSCs do not have worsened overall survival or
progression-free survival. Tumor cells detected by sensitive molecular methods in PBSC collections may be distinct from cells
contaminating marrow and appear to have limited utility in identifying patients with MM and B-cell NHL who would benefit
from purging strategies.
Kopp [6] Chemotherapy and G-CSF 60/MM Patients with >4.5 105 plasma cells/kg contaminating the PBSC graft received after high-dose chemotherapy have a significantly
reduced overall survival. Whether high contamination of grafts with plasma cells might reflect residual in vivo tumor mass prior
to stem cell transplantation and a generally more aggressive behavior of malignant myeloma cells in these patients, or whether
reinfused plasma cells contribute to an unfavorable course of disease remains to be determined.
Kornnacker [89] G-CSF or chemotherapy
and G-CSF
241/NHL Patients with disease recurrence within 1 year after transplant and those who had received autoSCTas second-line treatment had
significantly reduced survival by multivariate analysis, whereas FLIPI score, age, remission status at autoSCT, high-dose regimen,
and ex vivo purging had no impact.
Lopez-Perez [30] G-CSF alone (12 patients) and
chemotherapy plus
G-CSF (11 patients)
23/MM Patients with clonally free products were more likely to obtain complete response following transplant (64% versus 17%, P5.02)
and a longer progression-free survival (40 months in patients transplanted with polyclonal products versus 20 months with
monoclonal products, P5 .03). These results were consistent when the overall survival was considered, because it was better
in those patients with negative apheresis than in those with positive (83% versus 36% at 5 years from diagnosis, P5 .01). These
findings indicate that the presence of clonality rearranged V, D, JH segments is related to the response and outcome in MM
transplanted patients.
Schiller [69] Chemotherapy plus G-CSF 37/MM PBPCs are an effective form of purified hematopoietic support achieving substantial reduction in myeloma cell contamination. At
infused cell doses of greater than 2 106 CD340 cells/kg, this product provides safe, rapid, and sustained hematologic recovery
in patients receiving myeloablative chemotherapy. Whether this form of purified stem cell support will produce improved
progression-free survival in patients with MM will require further trials.
Stewart [90] Chemotherapy and G-CSF 190/MM This phase 3 trial demonstrated that although CD34 selection significantly reduces myeloma cell contamination in PBPC
collections, no improvement in disease-free or overall survival was achieved.
Vogel [91] Chemotherapy and G-CSF 74/MM Patients with graft contamination of >4.5  105 plasma cells kg21 had a high risk of early disease progression after high-dose
chemotherapy.
Vose [92] G-CSF alone 93/NHL Patients with aggressive NHL receiving HSC transplantation randomized to PBSC transplantation versus BM harvest
demonstrated improved neutrophil engraftment and platelet and RBC transfusion independence. The complete response rate
and event-free survival were not statistically different by randomization arm. Patients whose harvests were positive for minimal
residual disease by molecular analysis had poorer event-free survival.
Williams [93] Not reported 224/NHL Time to hematologic engraftment, response to autologous BM transplantation, and number of procedure-related deaths were
similar in purged and unpurged patients. The overall survival rate was 54% at 5 years in purged patients and 48.3% in unpurged
patients (P 5 .1813). The progression-free survival rate was 44.3% and 44.6%, respectively (P 5 .1961). Patterns of relapse,
including bone marrow relapse, were similar in both groups.
BM indicates bone marrow; CI, confidence interval; FLIPI, Follicular Lymphoma International Prognostic Index; HR, hazard ratio; HSC, hematopoietic stem cells, MM, multiple myeloma; NHL, non-Hodgkin lymphoma;
PBPC, peripheral blood progenitor cell; PCR, polymerase chain reaction; RR, response rate; PBSC, peripheral blood stem cell.
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strated that purging leads to clinical benefit [89].
Two phase 3 randomized trials compared patients
with MM who received autografts purged of tumor
cells (CD341-selected PBSC) with those with unse-
lected PBSCs [87,90]. Both studies used a highly
sensitive, tumor-specific PCR technique to identify
the Ig heavy chain sequence of the myeloma clone
and determine the level of tumor cell contamination.
Both studies achieved a large reduction in tumor bur-
den (approximately 1 to 6 log tumor load reduction),
but no significant differences were observed between
the 2 groups in terms of response, EFS/PFS, or OS.
Given these findings, the authors of each of these
phase 3 studies speculated that reinfused myeloma
cells may not be a significant cause of relapse, but
that failure to eradicate the disease within the patient
with high-dose chemotherapy may be a stronger con-
tributor to relapse. Findings showing allogeneic (and
therefore tumor-free) BM transplants for myeloma
following which patients had a high risk of relapse ap-
proaching 50% [107] likewise suggest that improved
disease eradication within the patient may be a more
important goal than purging tumor cells from the rein-
fused product. Similar clinical outcomes and results
have been reported for patients with NHL who re-
ceived tumor-purged products in a case-matched com-
parison study using the European Group for Blood
and Marrow Transplantation (EBMT) registry [93].
Mechanism of tumor cell mobilization and
metastatic potential
Tumor cells appear to increase, or are ‘‘mobi-
lized,’’ into the PB following treatment with standard
chemotherapy and radiation [4]. In preclinical models,
Biswas et al. [4] demonstrated that when established
tumors are treated with chemotherapy or radiation,
an increase in circulating tumor cells could be
measured, and that this increase in tumor cells results
in increased lung metastases. The observed tumor cell
mobilization and metastatic effect was blocked by neu-
tralizing antibodies to transforming growth factor-
beta (TGF-b). TGF-b is known to be a critical inducer
of epithelial mesenchymal transition (EMT), which
causes a morphologic and physiologic change in the
tumor cell, leading to increased migration and meta-
stases. Interestingly, in studies in which putative breast
cancer stem cells have been identified, TGF-b has
been demonstrated to have similar effects on the in-
duction of EMT in these cells [108]. Therefore, tumor
cell mobilization appears to occur following standard
cancer treatments, and although other factors may be
involved, this effect appears to be primarily driven by
the prometastatic effect of TGF-b.
The tumor microenvironment is now recognized
as a key factor in the growth of tumor cells. This
symbiotic relationship includes the production ofcytokines such as TGF-b and vascular endothelial
growth factor (VEGF) by the tumor that stimulate
the production of stroma, blood vessels, and other fac-
tors that provide the tumor with a supportive microen-
vironment in which to grow. Stromal cells produce and
express SDF-1, which engage tumor cell CXCR4 re-
ceptors and induce antiapoptotic signaling. Several
groups have demonstrated that blockade of CXCR4
with plerixafor or similar agents can sensitize tumor
cells to chemotherapy, increase their effectiveness,
and lead to prolonged survival of animals [109-113].
These data are the basis for ongoing clinical studies
investigating the use of plerixafor in combination
with chemotherapy or biological treatments for AML
and chronic lymphocytic leukemia. Therefore, even
though tumor cells might migrate/mobilize under
certain conditions such as CXCR4 inhibition, they
may readily undergo apoptosis, and their metastatic
potential may be diminished.CONCLUSION
The detection of tumor cells continues to remain
extremely difficult, given the low number of tumor
cells compared with normal cells and the large variety
of potential tumor types. The sensitivity and specificity
of the various tumor cell detection methods varies and
is highly dependent on the method used and the source
of the cells analyzed, making it difficult to compare re-
sults across studies published in the literature. Despite
these limitations, it has long been recognized that tu-
mor cell contamination occurs during themobilization
and collection of stem cells from patients withMMand
lymphoma following G-CSF or chemomobilization.
Tumor cell contamination following plerixafor admin-
istration appears to be similar or less than that follow-
ing G-CSF mobilization alone when the same number
of CD341 stem cells are collected.
Of critical importance is the relevance of tumor
cell mobilization on clinical outcome. It is possible
that tumor cells in the reinfused apheresis product
could be responsible for relapse. However, it is more
likely that relapse is because of the regrowth of residual
cancer in the patient following incomplete eradication
of tumor cells by high-dose chemotherapy and radia-
tion therapy. The latter scenario is demonstrated by
the significant relapse rate in cancer patients receiving
‘‘tumor-free’’ allogeneic stem cells from healthy do-
nors and the fact that in autologous transplants, the
most common sites of relapse are prior sites of disease
[92]. In addition, phase 2 and large, randomized phase
3 studies have demonstrated that even a large reduc-
tion in the number of tumor cells in the apheresis
product had no impact on clinical outcome as mea-
sured by disease-free survival or OS. In studies in
which tumor cell contamination was associated with
952 Biol Blood Marrow Transplant 17:943-955, 2011J. F. DiPersio et al.poorer OS, the correlation was only significant when
the level of tumor contamination was very high
(.4.5  105 cells/kg), as detected by flow cytometry.
Finally, the reinfusion with tumor cells during autolo-
gous HSC transplantation in MM and NHL patients
appears to have no influence on PFS or OS, even
when aggressive or indolent histologies are considered
separately. Collectively, these data suggest that im-
proved treatments to control and eliminate residual tu-
mor are needed and are critical for improving
outcomes with stem cell transplantation. New thera-
pies for hematologic malignancies, such as MM,
NHL, and AML, should focus on increasing the che-
mosensitivity of the tumor and eliminating residual
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